DENALI THERAPEUTICS INC (DNLI)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for DNLI
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| DNLI | Director | 54 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LXEO | Class I Director | 54 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
Tim Van Hauwermeiren has served on our board of directors since November 2025. He co-founded argenx SE and has served as its Chief Executive Officer since 2008. Since 2017, he has also served as a director of the company. In addition he has served as an independent director on the boards of public companies, including iTeos Therapeutics, RayzeBio, and Lexeo Therapeutics, as well as private company Aelin Therapeutics. Mr. Van Hauwermeiren has broad training and experience in biotech and innovation management. He holds a degree in BioEngineering from the University of Ghent and an executive M.B.A. from Vlerick Business School. We believe Mr. Van Hauwermeiren is qualified to serve on our board of directors because of his extensive experience in the life sciences industry and leadership experience as a founder and senior executive of a life sciences company.